Capricor Therapeutics Inc (NASDAQ: CAPR) has reported a loss for its second fiscal quarter (ending June 30) of $-0.35 versus a loss $-0.29 for the same period a year ago. This result fell short of the consensus estimate of $-0.33 by $-0.02. For the latest four quarters through June 30, E.P.S. were $-0.93 versus $-1.17 for the same period a year ago.
Recent Price Action
Capricor Therapeutics Inc (NASDAQ: CAPR) stock suffered a large decline of -9.0% on 8/7/24. The stock closed at $3.56. Trading volume in this decline was normal. The stock has declined -12.7% during the last week but has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, CAPR is expected to continue to be Value Creation neutral.
Capricor Therapeutics has a current Value Trend Rating of C (Low Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Capricor Therapeutics has a very low Appreciation Score of 4 but a good Power Rating of 81, with the Low Neutral Value Trend Rating the result.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment